PAVmed (NASDAQ:PAVM) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

PAVmed (NASDAQ:PAVM) had its price target upped by Ascendiant Capital Markets from $56.00 to $57.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Weiss Ratings downgraded PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, PAVmed has a consensus rating of “Hold” and an average price target of $57.00.

PAVmed Stock Performance

NASDAQ:PAVM opened at $5.32 on Thursday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.19 and a current ratio of 1.19. PAVmed has a fifty-two week low of $3.85 and a fifty-two week high of $28.44. The company has a 50 day simple moving average of $5.21 and a two-hundred day simple moving average of $7.34. The company has a market capitalization of $42.54 million, a PE ratio of -0.33 and a beta of 0.54.

Institutional Trading of PAVmed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in PAVmed in the 2nd quarter worth about $102,000. Jane Street Group LLC increased its stake in PAVmed by 392.9% in the 2nd quarter. Jane Street Group LLC now owns 52,676 shares of the company’s stock valued at $32,000 after buying an additional 41,990 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of PAVmed by 74.8% during the 4th quarter. Geode Capital Management LLC now owns 168,832 shares of the company’s stock worth $40,000 after buying an additional 72,258 shares in the last quarter. Finally, Two Seas Capital LP purchased a new position in shares of PAVmed in the 2nd quarter worth approximately $2,742,000. 19.93% of the stock is owned by institutional investors.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.